Membrane Potential-Dependent Inhibition of the Na⁺,K⁺-ATPase by para-Nitrobenzyltriethylammonium Bromide^S

R. Daniel Peluffo and Joshua R. Berlin

Department of Pharmacology and Physiology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey

Received December 1, 2011; accepted March 28, 2012

ABSTRACT

Membrane potential ($V_{\rm M}$)-dependent inhibitors of the Na⁺,K⁺-ATPase are a new class of compounds that may have inherent advantages over currently available drugs targeting this enzyme. However, two questions remain unanswered regarding these inhibitors: (1) what is the mechanism of $V_{\rm M}$ -dependent Na⁺,K⁺-ATPase inhibition, and (2) is their binding affinity high enough to consider them as possible lead compounds? To address these questions, we investigated how a recently synthesized $V_{\rm M}$ dependent Na⁺,K⁺-ATPase inhibitor, *para*-nitrobenzyltriethylamine (*p*NBTEA), binds to the enzyme by measuring the extracellular *p*NBTEA concentration and $V_{\rm M}$ dependence of ouabain-sensitive transient charge movements in whole-cell patch-clamped rat cardiac ventricular myocytes. By analyzing the kinetics of charge movements and the steady-state distribution of charge, we show

Introduction

Interest in small-molecule inhibitors of the P-type Na⁺,K⁺-ATPase has reemerged with the realization that pharmacological interventions targeting this enzyme might be relevant in a diverse array of disease processes. The Na⁺,K⁺-ATPase is well known for its critical role in developing and maintaining electrochemical gradients for Na⁺ and K⁺ across the plasma membrane (Glynn, 1985). In this role, the Na⁺,K⁺-ATPase controls contractility of cardiac muscle cells by regulating cell Ca²⁺ loading via the sarcolemmal Na⁺/Ca⁺ exchanger (Eisner et al., 1984). Manipulating the Na⁺ electrochemical gradient, and thereby cellular Ca²⁺, by Na⁺,K⁺-ATPase inhibition is believed to be the basis for the inotropic actions of the cardiac glycoside, digoxin (Akera and Brody, 1977), a classic pharmacological agent and, until

that the $V_{\rm M}$ -dependent properties of *p*NBTEA binding differ from those for extracellular Na⁺ and K⁺ binding, even though inhibitor binding is competitive with extracellular K⁺. The data were also fit to specific models for *p*NBTEA binding to show that *p*NBTEA binding is a rate-limiting $V_{\rm M}$ -dependent reaction that, in light of homology models for the Na⁺,K⁺-ATPase, we interpret as a transfer reaction of *p*NBTEA from a peripheral binding site in the enzyme to a site near the known K⁺ coordination sites buried within the transmembrane helices of the enzyme. These models also suggest that binding occurs with an apparent affinity of 7 μ M. This apparent binding affinity suggests that high-affinity $V_{\rm M}$ -dependent Na⁺,K⁺-ATPase inhibitors should be feasible to design and test as specific enzyme inhibitors.

recently, a first-line treatment for congestive heart failure (Gheorghiade et al., 2006). Mutations in the enzyme's α subunit have been linked to autosomal dominant forms of migraine (De Fusco et al., 2003) and Parkinson's disease (Blanco-Arias et al., 2009). A signaling function has also been postulated for the Na⁺,K⁺-ATPase via Src-dependent pathways (Haas et al., 2000; Tian et al., 2006). For example, the cardiac glycoside ouabain has been shown to regulate cell junctional contacts (Larre et al., 2010) and cell proliferation (Tian et al., 2009) at concentrations that have little or no significant effect on net ion transport. Such reports have generated interest in Na⁺,K⁺-ATPase inhibitors as potential chemotherapeutic agents (for review, see Newman et al., 2008) and suggest that the Na⁺,K⁺-ATPase might be an attractive drug target beyond its established roles in inotropic and antiarrhythmic therapeutics.

Cardiac glycosides are the most widely studied Na⁺,K⁺-ATPase inhibitors. Mutagenesis studies have identified amino acids in the enzyme's α subunit that are important for ouabain binding (for review, see Lingrel, 2010) and recent high-resolution structures of the Na⁺,K⁺-ATPase include bound ouabain (Ogawa et al., 2009; Yatime et al., 2011). Cardiac glycosides have been synthesized and tested in more

This work was supported by the National Institutes of Health National Institute of General Medical Sciences [Grant R01-GM057253] (to J.R.B.) and National Institutes of Health National Heart, Lung, and Blood Institute [Grant R01-HL076392] (to R.D.P.).

Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

http://dx.doi.org/10.1124/mol.111.077008.

S The online version of this article (available at http://molpharm. aspetjournals.org) contains supplemental material.

than five decades of drug discovery efforts (Glynn, 1964; Güntert and Linde, 1981; Gobbini and Cerri, 2005). In addition, other high-affinity Na⁺,K⁺-ATPase inhibitors, such as cassaine (Tobin et al., 1975), have been reported and have served as the basis for recent efforts to synthesize novel enzyme inhibitors (Gobbini and Cerri, 2005). However, none of these inhibitors can distinguish between Na⁺,K⁺-ATPase located in different cellular or tissue compartments in which the enzyme resides. Selectivity in Na⁺,K⁺-ATPase inhibition, however, may provide advantages in treatment of congestive heart failure and is certainly relevant if Na⁺,K⁺-ATPase inhibitors are to be developed as chemotherapeutic agents. For this reason, the search for novel Na⁺,K⁺-ATPase inhibitors is a promising area of drug discovery.

In a previous study, we identified a compound, benzyltriethylamine (BTEA), that inhibits the Na⁺,K⁺-ATPase in a membrane-potential $(V_{\rm M})$ -dependent fashion such that enzyme block is more pronounced at negative potentials (Peluffo et al., 2004). This compound seems to bind at a K⁺ coordination site within the enzyme although, unlike K⁺, it is neither occluded nor transported. What is intriguing about BTEA is that it is the first reported $V_{\rm M}$ -dependent blocker of the Na^+, K^+ -ATPase, although several other V_M -dependent inhibitors have since been reported (Peluffo et al., 2009; Ratheal et al., 2010). These compounds offer the possibility of a class of Na⁺,K⁺-ATPase inhibitors that distinguish, to some degree, enzyme located in electrically polarized cells versus enzyme in cells with depolarized membrane potentials. As will be presented under Discussion, this property might be useful for the treatment of congestive heart failure. In addition, V_{M} -dependent Na⁺, K⁺-ATPase inhibitors might also be useful as chemotherapeutic agents.

BTEA is a low-affinity blocker, used in the millimolar concentration range (Forbush, 1988; Peluffo et al., 2004). For this reason, the para-nitro derivative of BTEA, pNBTEA, was synthesized and found to have similar $V_{\rm M}$ -dependent inhibitory effects on the Na⁺,K⁺-ATPase, but at a much lower concentration (Peluffo et al., 2009). These results were promising for development of similar compounds as highaffinity Na⁺,K⁺-ATPase inhibitors, but two important questions remained unanswered in previous work. First, although BTEA and *p*NBTEA seem to bind at a K^+ site in the enzyme, their mechanism of $V_{\rm M}$ -dependent inhibition was not studied. Using pre-steady-state binding kinetics, we have compared different models for $V_{\rm M}$ -dependent binding in the present work to determine which best describes pNBTEA inhibition of the Na⁺,K⁺-ATPase. Second, we have not previously determined the apparent affinity for inhibition of the Na^+, K^+ -ATPase by *p*NBTEA. Our analysis here shows it is a much more potent inhibitor than the parent BTEA. These results suggest that further development of $V_{\rm M}$ -dependent Na⁺,K⁺-ATPase inhibitors is warranted.

Materials and Methods

Whole-Cell Patch Clamp. Ventricular myocytes were enzymatically isolated from rat hearts and voltage-clamped with patch electrodes (1.0–1.5 M Ω) as published previously (Ishizuka et al., 1996). Animals were treated according to the *Guide for the Care and Use of Laboratory Animals* (Institute of Laboratory Animal Resources, 1996) in a protocol approved by our institutional animal care and use committee. For measurements of transient charge movements, protocols were followed as outlined previously (Peluffo and Berlin, 1997; Peluffo et al., 2009). Experiments were performed at 18–20°C with Na⁺- and K⁺-free superfusion solutions containing 145 mM tetramethylammonium chloride, 2.3 mM MgCl₂, 0.2 mM CdCl₂, 5.5 mM dextrose, and 10 mM HEPES (pH 7.4 with Tris). The bromide salt of *p*NBTEA was added to this solution at the indicated concentrations. The patch electrode solution contained 130 mM K⁺, 20 mM tetraethyl ammonium chloride, 9.1 mM MgCl₂, 0.7 mM ATP-Mg²⁺ salt, 30 mM phosphate (H₂PO₄⁻ + HPO₄²⁻), 1 mM EGTA, 66 mM aspartic acid, and 10 mM HEPES, pH 7.3 (20°C). The magnesium phosphate concentration was calculated with MaxChelator to be 1.3 mM.

The experimental procedure to measure extracellular pNBTEA transient charge movements was to first superfuse a voltageclamped myocyte with a *p*NBTEA-containing Na⁺- and K⁺-free solution and determine the current-voltage relationship between -160and +100 mV two times, separated by 1 min. The myocyte was then perfused for 2 min with the same solution that also included 1 mM ouabain, and another current-voltage relationship was determined before switching back to the ouabain-free solution. Our previous experiments (Peluffo et al., 2009) have shown that 2 min of exposure to 1 mM ouabain is sufficient to completely block quaternary aminedependent transient charge movements. Currents measured before and 2 min after addition of ouabain were then subtracted to yield ouabain-sensitive transient currents. These currents were integrated and divided by cell capacitance to yield a outbain-sensitive charge (q; inunits of femtocoulombs per picofarad). A more complete description of the experimental protocol is found in Peluffo et al. (2009).

Analysis, Curve-Fitting, and Model Selection. Data are presented as means \pm S.E.M. for the indicated number of replicates or cells. Cell capacitance was calculated as the integral of current elicited with 5-mV pulses. Indicated functions were fit to the data with a nonlinear least-squares algorithm available in commercial software (SigmaPlot, Systat Software Inc., San Jose, CA) using statistical weights proportional to (S.E.M.)⁻¹. Different binding models were evaluated by applying a second-order Akaike information criterion and Akaike weights (Yamaoka et al., 1978; Burnham and Anderson, 2002; González-Lebrero et al., 2002; Montes et al., 2004). The Akaike information criterion (AIC_c) with a limited data set was calculated for each model as

$$AIC_{c} = -2ln(L(\theta|y)) + 2K\left(\frac{n}{n-K-1}\right)$$

where $L(\theta|y)$ is the root mean square of the residuals between the data and fitted model function, n is the sample size, and K is the number of estimated parameters. To determine the weight of evidence that a particular model is actually the best model to describe the data, Akaike weights (w_i) were calculated as

$$w_{i} = \frac{\exp(-0.5\text{AIC}_{i})}{\sum\limits_{r=1}^{N} \exp(-0.5\text{AIC}_{r})} \qquad 0 \le w_{i} \le 1$$

where AIC_i is the AIC_c for the *i*th function out of the total number (*N*) of functions tested. The likelihood that the *i*th model is the best model for the data increases as w_i approaches a value of 1 (Burnham and Anderson, 2002). Experiments using 100 μ M *p*NBTEA have been reported in Peluffo et al. (2009); however, analysis of the data set at all tested *p*NBTEA concentrations is presented here for the first time.

Reagents. Reagents were from Sigma-Aldrich (St. Louis, MO) and were of analytical grade or higher. *p*NBTEA was synthesized as outlined previously (Peluffo et al., 2009).

Results

Peluffo et al. (2009) showed that BTEA competitively inhibits $\rm ^{86}Rb^+$ occlusion by the Na⁺,K⁺-ATPase. In the same study, pNBTEA was found to be a $V_{\rm M}$ -dependent inhibitor by

examining the effects of 100 μ M pNBTEA on steady-state Na⁺,K⁺-pump current and *p*NBTEA-dependent pre-steadystate transient charge movements at different membrane potentials. To gain greater insight into the mechanism of enzyme block by pNBTEA, we have also conducted measurements of transient charge movements with 33 and 300 μ M concentrations of the quaternary amine added to the perfusion solution in patch-clamped rat ventricular myocytes (see Materials and Methods). Figure 1, A to C, shows representative 1 mM ouabain-sensitive difference currents recorded when the membrane potential was stepped from the holding potential, -40 mV, to 0 mV for 100 ms, before returning to the holding potential. Our previous work (Peluffo and Berlin, 1997; Peluffo et al., 2009) has shown that 1 mM ouabain is sufficient to completely block extracellular ion-dependent charge movements in rat ventricular myocytes. The ouabain sensitivity of these currents demonstrates that they arise from a $V_{\rm M}$ -dependent process in the Na⁺,K⁺-ATPase. In the absence of pNBTEA, ouabain-sensitive transient currents were not observed (Peluffo et al., 2009). Thus, these currents show that the inhibition of the Na⁺,K⁺-ATPase by the positively charged pNBTEA involves at least one $V_{\rm M}$ -dependent reaction.

Ouabain-sensitive charge movements reflect a change of ion binding by the Na⁺, K⁺-ATPase in response to a change in $V_{\rm M}$ (Gadsby et al., 1993; Peluffo and Berlin, 1997). With transported cations (i.e., Na⁺ and K⁺), the kinetics of these charge movements are limited by subsequent electroneutral reactions involved in ion occlusion by the enzyme (Gadsby et



Fig. 1. Ouabain-sensitive pre–steady-state currents with various *p*NBTEA concentrations. Currents were recorded in response to a 100-ms depolarization to 0 mV in the presence and absence of 1 mM ouabain in superfusion solutions containing 33 μ M (A), 100 μ M (B), and 300 μ M *p*NBTEA (C). Ouabain-sensitive difference currents are displayed without any capacitance correction or leak subtraction. The solid curve through the decaying phase shows the exponential function fit to the data. Note the change in the time scale. The rate of current decay (k_{tot}) is displayed as a function of $V_{\rm M}$ (D) for 33 μ M (\bigtriangledown), 100 μ M (\oplus), and 300 μ M *p*NBTEA (\bigcirc). The solid curves were determined by fitting the entire data set to eq. 1. The calculated values of k_r^0 and k_r^0 were 58,600 \pm 2000 s⁻¹ M⁻ⁿ and 282 \pm 9 s⁻¹, respectively.

al., 1993; Hilgemann, 1994; Wuddel and Apell, 1995). However, as we have previously shown, organic quaternary amine inhibitors of the Na⁺,K⁺-ATPase, such as *p*NBTEA, are not occluded (Peluffo et al., 2009). Therefore, the kinetics of *p*NBTEA-dependent transient charge movements are a direct measure of the rate of quaternary amine binding reactions.

As shown in Fig. 1, A to C, depolarization produced an outward current transient and hyperpolarization an inward current transient, consistent with the movement of a positive charge in the membrane electric field. An exponential function provided a good fit to the decaying portion of the current traces in Fig. 1, A to C, indicating a pseudo-first-order process. This fitting allowed us to derive a rate (k_{tot}) for the change in *p*NBTEA binding after a $V_{\rm M}$ jump. The rate of decay of the transient current increased at higher *p*NBTEA concentrations (Fig. 1D), as would be expected for a pseudo-first-order ligand binding reaction. Thus, the transient currents shown here result from the $V_{\rm M}$ -dependent binding of the quaternary amine as it inhibits the Na⁺,K⁺-ATPase.

The calculated $k_{\rm tot}$ is plotted as a function of $V_{\rm M}$ for all pNBTEA concentrations tested in Fig. 1D. This k_{tot} - V_M relationship has several interesting features. The relationship is U-shaped for all pNBTEA concentrations tested. This feature distinguishes quaternary amine binding kinetics from those for ions that are bound, occluded, and transported by the Na^+, K^+ -ATPase (see *Discussion*). Of interest, the V_M at which $k_{\rm tot}$ was a minimum shifted to more positive $V_{\rm M}$ with increasing pNBTEA concentration, and the kinetics seemed to be more $V_{\rm M}$ -dependent at positive potentials. To describe the pNBTEA- and $V_{\rm M}$ -dependent properties of $k_{\rm tot}$, the entire data set was fitted simultaneously with eq. 1, which is derived assuming that first-order kinetics of pNBTEA-dependent transient currents reflect a system in which Na⁺,K⁺-ATPase is amine-bound or free (i.e., a pseudo-two-state model),

$$k_{\text{tot}} = k_{\text{f}}^{0} [Q]^{n} \exp\{-\delta \lambda_{\text{Q}} F V_{\text{M}} / RT\} + k_{\text{r}}^{0} \exp\{(1-\delta) \lambda_{\text{Q}} F V_{\text{M}} / RT\}$$
(1)

where $k_{\rm f}^{0}$ and $k_{\rm r}^{0}$ are the forward and reverse rate constants for pNBTEA binding at 0 mV, [Q] is the extracellular pNBTEA concentration, n is the Hill coefficient for the reaction, λ_{Q} is the apparent charge moved in the V_{M} -dependent reaction, δ is a proportionality coefficient that distributes the effect of the electric field between the forward and backward reactions, and F, R, and T are the Faraday constant, the gas constant, and the absolute temperature, respectively. The calculated values for $k_{\rm f}^{0}$ and $k_{\rm r}^{0}$ are given in the legend to Fig. 1. This calculation showed that the apparent charge (λ_{Θ}) equaled 0.41 \pm 0.01, equivalent to a full charge dissipating 41% of the electric field during enzyme inhibition. This value was not significantly different from the 37% of the electric field dissipated by extracellular K⁺ during its activation of ion transport by the Na⁺,K⁺-ATPase (Peluffo and Berlin, 1997). This similarity along with the competitive nature of pNBTEA enzyme inhibition led us to conclude that these amines were binding at a K⁺ coordination site in the enzyme (Peluffo et al., 2009). The proportionality constant δ was $0.32 \pm 0.01.$ This value reflects the steeper $V_{\rm M}$ dependence of $k_{
m tot}$ at positive potentials and the shift in the $V_{
m M}$ at which $k_{
m tot}$ reaches a minimum with increased pNBTEA concentration



Fig. 2. *p*NBTEA concentration and $V_{\rm M}$ dependence of charge movement. Charge (q) was calculated as the integral of the ouabain-sensitive difference current recorded in response to a step change in $V_{\rm M}$ ($q_{\rm ON}$) divided by cell capacitance during superfusion with solutions containing 33 (\heartsuit), 100 (\bullet), and 300 μ M *p*NBTEA (\bigcirc). A, charge. B, charge normalized to $q_{\rm TOT}$ calculated by fitting the data at each *p*NBTEA concentration with the following Boltzmann equation: $q = q_{\rm min} + q_{\rm TOT}/(1 + \exp[-(V_{\rm M} - V_{\rm q})/z_{\rm q}])$ Values for the best fit parameters are given in Table 1.

(see eq. 1). The Hill coefficient was 0.52 ± 0.01 , a value indicative of negative cooperativity in *p*NBTEA binding to the enzyme, which implies that more than one amine molecule binds to the enzyme.

To further describe the $V_{\rm M}$ dependence of *p*NBTEA binding, charge (*q*) moved in response to step changes in $V_{\rm M}$ was calculated by integrating the area under ouabain-sensitive difference currents. The current integral at the beginning of the $V_{\rm M}$ step, $q_{\rm ON}$, was the same as the current integral, $q_{\rm OFF}$, measured after returning to the holding potential. Equality of $q_{\rm ON}$ and $q_{\rm OFF}$ is indicative of a reversible binding process for the quaternary amine (Peluffo and Berlin, 1997; Peluffo et al., 2009).

The values for $q_{\rm ON}$ were plotted against $V_{\rm M}$, before (Fig. 2A) and after normalization to $q_{\rm TOT}$, the total amount of charge moved (Fig. 2B). The data at each *p*NBTEA concentration were also fitted with a Boltzmann equation that describes the probability of the enzyme being in a *p*NBTEA-bound state as a function of $V_{\rm M}$. Best-fit parameter values are shown in Table 1.

This analysis revealed $V_{\rm M}$ -dependent properties of pNBTEA binding reactions as well as limitations of the pseudo-two-state model analysis. q_{TOT} was unchanged with *p*NBTEA concentration, as if $V_{\rm M}$ could drive *p*NBTEA into or out of a fixed number of Na⁺,K⁺-ATPase binding sites over the range of concentrations tested; however, the quantity of charge moved by a large negative step in $V_{\rm M}$ $(q_{\rm MIN})$ from the holding potential decreased as the pNBTEA concentration was increased. This shift in the $V_{\rm M}$ dependence of charge movement, shown more clearly in Fig. 2B, is consistent with increased amine binding at the holding potential as the pNBTEA concentration is increased (i.e., at a higher amine concentration, a smaller fraction of total Na⁺,K⁺-ATPase remains to be driven into the bound state at negative $V_{\rm M}$). The magnitude of the shift in charge movement, 26 mV per e-fold change in *p*NBTEA concentration (Supplemental Fig. 1), would be consistent with one charge dissipating the equivalent of the entire electric field across the cell membrane during pNBTEA binding. Thus, $V_{\rm M}$ dependence of binding calculated in this manner seems to be much stronger than that determined by the value for λ_{Q} , the apparent charge calculated from the kinetics of transient current decay (Fig. 1).

Eyring rate theory suggests that the shift in charge movement depends on the effective charge of the $V_{\rm M}$ -dependent reaction and the molecularity of that reaction (Peluffo, 2004). Because the Hill coefficient for transient currents does not equal 1 (Fig. 1), the molecularity of the reaction is unknown, although clearly more than one *p*NBTEA molecule is involved in these reactions. Thus, there is no a priori expectation that $V_{\rm M}$ -dependent parameters derived from analyses of kinetics and quantity of charge movement will be consistent because the pseudo-two-state model used for analysis of data in Figs. 1 and 2 accommodates neither the molecularity nor the type of binding reaction.

To understand more about pNBTEA binding to the Na⁺,K⁺-ATPase, different ligand binding models were evaluated to determine which provides the best fit to the data. In evaluating potential binding models for pNBTEA, random schemes were excluded because Rb⁺ binding to the Na⁺,K⁺-ATPase is an ordered process (Forbush, 1987; González-Lebrero et al., 2002). Given that pNBTEA seems to bind at an extracellular K⁺ coordination site, the assumption of ordered binding is also likely to be valid. Furthermore, the effect of BTEA on Rb⁺ occlusion (Peluffo et al., 2009) is well described by postulating two amine binding sites in the enzyme. Although a greater number of sites cannot be excluded, there is no obvious rationale to include more. For this reason, only models with two pNBTEA binding sites were evaluated. The monoexponential decay of pNBTEA-activated transient charge movements also suggests that either 1) rate-limiting $V_{\rm M}$ -dependent reactions have similar kinetics or 2) multiple $V_{\rm M}$ -dependent reactions have very different kinetics. In both cases,

TABLE 1

Pseudo-two-state Boltzmann function parameters for the $V_{\rm M}$ dependence of q

Parameter		[pNBTEA]	
	$33 \ \mu M$	$100 \ \mu M$	$300 \ \mu M$
$q_{\rm TOT}({\rm fC/pF})$	13.7 ± 0.6	14.9 ± 0.4	14.0 ± 0.5
$q_{\rm MIN}$ (fC/pF)	-8.3 ± 0.5	-6.1 ± 0.2	-3.6 ± 0.2
V_{α} (mV)	-57.0 ± 3.4	-27.1 ± 1.8	0.5 ± 2.9
z_q^{-1}	0.56 ± 0.04	0.65 ± 0.03	0.72 ± 0.06

these schemes simplify to an ordered reaction with a single $V_{\rm M}\text{-}{\rm dependent}$ reaction.

In a broad sense, ordered reaction schemes fall into two categories shown as Schemes A and B. Scheme A is a classic sequential reaction mechanism for a two-site enzyme in which pNBTEA binding at site 1 and/or site 2 can be $V_{\rm M}$ dependent. The rates of the binding reactions are described by pseudo-first-order forward (k_x) and reverse (k_{-x}) rate constants (where x = 1, 2). Because the decay of *p*NBTEA-dependent transient currents is exponential, it can be assumed that for Scheme A either the sum of $k_1 + k_{-1}$ is similar to the sum of $k_2 + k_{-2}$ or these sums are very different. Scheme B is based on the work of Glynn et al. (1985), Forbush (1987), and González-Lebrero et al. (2002), whose analysis of Rb⁺ occlusion kinetics by the Na⁺.K⁺-ATPase suggested that Rb⁺ binding is in rapid equilibrium with the Na⁺,K⁺-ATPase but the sequential binding of each Rb⁺ is limited by the accessibility of the Rb⁺ binding sites, as if a gate with low open probability ("leaky gate") limited access to the ion coordination sites. Because BTEA is not occluded (Peluffo et al., 2009), we have instead substituted a rate-limiting reaction of the pNBTEA-bound enzyme, illustrated in Scheme B as transfer of the bound amine between the first and second binding sites (see Discussion). Any or all of these reaction steps can be $V_{\rm M}$ -dependent.

Given these two reaction schemes, there are a total of 10 possible model systems (3 for Scheme A and 7 for Scheme B) that derive from assigning $V_{\rm M}$ dependence to any one or combination of reaction steps. Some of these model systems are mathematically identical so that only eight model systems were fitted to the data for the $k_{\rm tot}$ - $V_{\rm M}$ relationship. Most models could not be fitted to the data without collapsing to a simpler system. Of the remaining models, the best-fitting models representative of Scheme A and Scheme B are presented in Fig. 3 for the $k_{\rm tot}$ - $V_{\rm M}$ relationship. Because these models have different numbers of free parameters, evaluations of goodness-of-fit were made using an Akaike information criterion (AIC_c).

The best-fitting models for Schemes A and B both tracked the experimental data well (see supplemental data for the fitted functions and best-fit parameter values). However, it is clear that the Scheme B model provided the better fit. This graphical impression is substantiated by the AIC_c for Scheme A (AIC_c = 321.2) and for Scheme B (AIC_c = 226.8), which provide an Akaike weight (w_i) for Scheme A that approaches a value of 0, meaning that the model is highly unlikely, whereas the w_i for Scheme B approaches a value of 1, meaning that this model is quite likely to be the best one describing the $V_{\rm M}$ and *p*NBTEA concentration dependence of $k_{\rm tot}$ (see *Materials and Methods*). From this analysis, we conclude that the $V_{\rm M}$ -dependent step in *p*NBTEA inhibition of the Na⁺, K⁺-ATPase occurs as a rate-limiting reaction of the

$$E_{\odot}^{\circ} \xleftarrow{k_{1}(V_{M})}{k_{-1}(V_{M})} E_{\odot}^{\bullet} \xleftarrow{k_{2}(V_{M})}{k_{-2}(V_{M})} E_{\bullet}^{\bullet}$$
Scheme A
$$E_{\odot}^{\circ} \xleftarrow{K_{a1}(V_{M})}{k_{\odot}(V_{M})} E_{\odot}^{\bullet} \xleftarrow{k_{2}(V_{M})}{k_{2}(V_{M})} E_{\bullet}^{\circ} \xleftarrow{K_{a2}(V_{M})}{k_{2}(V_{M})} E_{\bullet}^{\circ}$$

Scheme B



Fig. 3. Fitting charge movement kinetics with specific *p*NBTEA binding models. Data points are reproduced from Fig. 1D. Curves represent the functions solved for the best fit models based on Scheme A (A) and Scheme B (B) using eqs. A6 and B9, respectively. These equations and their best fit parameter values are listed in the supplemental data. Symbols are as indicated in Fig. 1D.

amine-bound enzyme. As presented under *Discussion*, we believe that this $V_{\rm M}$ -dependent step represents the transfer of bound *p*NBTEA from site 1 to site 2 within the enzyme.

Figure 4 shows the functions fitted to the q- $V_{\rm M}$ data for the same Scheme A and B models (see supplemental data). Again, both models seem to fit these steady-state data quite well; however, the model based on Scheme B seems to provide the better fit. In addition, both models show that the membrane electric field has a similar effect on the $V_{\rm M}$ dependence of charge kinetics and quantity. With Scheme A, binding of the first and second amine molecule is $V_{\rm M}$ -dependent, together dissipating between 80 and 100% of the electric field, for both charge kinetics (Fig. 3A) and quantity (Fig. 4A). Scheme B is also somewhat successful with the single $V_{\rm M}$ -dependent reaction predicted to dissipate between 41 and 64% of the membrane electric field (see supplemental data

6 Peluffo and Berlin

for values of $\lambda_{\rm Q}$) for charge kinetics (Fig. 3B) and quantity (Fig. 4B). Thus, to a large degree, the apparent contradiction regarding the effectiveness of the membrane electric field on charge movement parameters derived from using a more generalized pseudo-two-state model is overcome by using a specific model that accounts for the molecularity of amine binding to the Na⁺,K⁺-ATPase.

What is interesting about the best-fit functions for Scheme B is the prediction that the first *p*NBTEA binds to the Na⁺,K⁺-ATPase with high affinity. From the $V_{\rm M}$ dependence of steady-state charge distribution, the model calculates an apparent affinity of 7 μ M ($K_{\rm D1} = 1/K_{\rm a1} = 6.9 \,\mu$ M). Consistent with the negative cooperativity shown in Fig. 1, the second amine molecule binds with lower apparent affinity (e.g., $K_{\rm D2} = 1/K_{\rm a2} = 65 \,\mu$ M from the $V_{\rm M}$ dependence of steady-state distribution of charge) (See supplemental data for parameter values when eq. B11 is solved.) Our previous experiments showed that binding of one molecule of *p*NBTEA inhibits the Na⁺,K⁺-ATPase (Peluffo et al., 2009). Thus, we conclude that the effect of negative $V_{\rm M}$ is to increase apparent affinity by driving the amine into the second binding site within the enzyme.

Fig. 4. Fitting the q- $V_{\rm M}$ relationship with specific *p*NBTEA binding models. Data points are reproduced from Fig. 2A. Curves show the functions solved for the best-fit models based on Scheme A (A) and Scheme B (B) using eqs. A9 and B11, respectively. These equations and their best fit parameter values are listed in the Supplemental Data. Symbols are as indicated in the legend to Fig. 2.

Discussion

In this report, pNBTEA reaction kinetics with the Na⁺,K⁺-ATPase were examined. We reported the first $V_{\rm M}$ -dependent Na⁺,K⁺-ATPase inhibitor, BTEA (Peluffo et al., 2004), and subsequently an initial characterization of its para-nitro derivative, pNBTEA (Peluffo et al., 2009). These compounds are competitive inhibitors of K⁺ activation of the Na⁺,K⁺-ATPase hydrolytic activity, extracellular K⁺ activation of steady-state ion transport, and ${}^{86}\text{Rb}^+$ occlusion. Their V_{M} dependence of inhibition, dissipating approximately 40% of the membrane electric field, is similar to that for extracellular K^+ activation of the enzyme (Peluffo and Berlin, 1997), when analyzed using a pseudo-two-state model to describe binding. Our interpretation of these data is that these compounds bind at a K⁺ coordination site in the enzyme. In a recent study, guanidinium, acetamidinium, and formamidinium ions have also been reported to be $V_{\rm M}$ -dependent inhibitors of the Na⁺,K⁺-ATPase (Ratheal et al., 2010). With the discovery of these $V_{\rm M}$ -dependent inhibitors, we have begun to consider whether similar compounds can be developed into a useful class of Na⁺,K⁺-ATPase inhibitors. To explore this question, a more in-depth investigation of pNBTEA was undertaken to answer two questions relevant to its utility as a $V_{\rm M}$ -dependent enzyme inhibitor.

First, what is the mechanism of pNBTEA $V_{\rm M}$ -dependent Na^+, K^+ -ATPase inhibition? BTEA and *p*NBTEA seem to bind at an extracellularly accessible K⁺ coordination site; however, they are neither occluded nor transported by the enzyme (Peluffo et al., 2004, 2009). pNBTEA binding also does not conform to the properties of ion binding in an ion well. $V_{\rm M}$ -dependent binding of Na⁺ and K⁺ in the Na⁺,K⁺-ATPase are diffusion-limited processes accompanied by slow conformational changes of the enzyme (Gadsby et al., 1993; Wuddel and Apell, 1995; Peluffo and Berlin, 1997) in which ion diffusion to its coordination site is $V_{\rm M}$ -dependent, whereas accompanying enzyme conformational changes seem to move little charge in the membrane electric field. For this reason, the proportionality coefficient " δ " in eq. 1 is approximately equal to 1 for K^+ , meaning k_{tot} is an asymptotic function of $V_{\rm M}$ (Peluffo and Berlin, 1997). In contrast, the properties of transient charge movements and our modeling calculations show that V_{M} -dependent pNBTEA binding must be much slower than would be expected for a diffusionlimited process. Kinetics of pNBTEA-dependent transient charge movements, measured as k_{tot} , have a U-shaped dependence on $V_{\rm M}$ that is reflected in the value of $\delta = 0.32$, a value showing that the effect of the membrane electric field on forward and reverse binding reaction kinetics is experimentally measurable. This condition cannot occur when a $V_{\rm M}$ -dependent diffusion-limited process is kinetically limited by a slow electroneutral reaction (i.e., a conformational change). The fact that model Scheme B yields a far better fit to the data than Scheme A is also consistent with the $V_{\rm M}$ dependent step being rate-limiting. Scheme B also stipulates that a rapid binding process occurs without movement of charge in the membrane electric field. This initial binding step is then followed by a slow charge moving reaction step. Thus, *p*NBTEA binding is clearly distinct from the mechanism involved in $V_{\rm M}$ -dependent extracellular K⁺ binding.

What is the $V_{\rm M}$ -dependent reaction that occurs during pNBTEA binding? Our present and previous data suggest a



possible mechanism. Two general types of $V_{\rm M}$ -dependent reaction mechanisms are possible with a pNBTEA-bound enzyme. First, $V_{\rm M}$ dependence can arise from movement of intrinsic charges in the protein during a conformational change, and second, pNBTEA could move within the electric field even after binding. With Na⁺- and K⁺-dependent reactions, significant movement of intrinsic protein charges has not been observed during ion binding (Gadsby et al., 1993; Hilgemann, 1994; Wuddel and Apell, 1995; Peluffo and Berlin, 1997). There is no obvious reason to infer that such movements would become apparent after pNBTEA binding, so this first mechanism seems unlikely. As to the second possibility, simulations of BTEA binding to a homology model of the Na⁺, K⁺-ATPase α subunit [with sarco(endo)plasmic reticulum Ca²⁺-ATPase structure 3B9B as a template] suggest that there are two amine sites in the enzyme (Peluffo et al., 2009). One of those sites is located at the extracellular surface of the protein in a wide vestibule with an electronegative surface charge. The second site is located within the transmembrane domain between helices 4 and 6 at a K⁺ coordination site. We have postulated that the first site is outside the membrane electric field, whereas the second site is in the field such that extracellular K⁺ or BTEA binding dissipates approximately one-third of the total electric field. This postulate could explain why most quaternary amine blockers of the Na $^+$,K $^+$ -ATPase are not $V_{\rm M}$ -dependent inhibitors (Peluffo et al., 2009); i.e., they would have low affinity for the second quaternary amine site located within the enzyme's transmembrane domain. Thus, data and modeling are consistent with the $V_{\rm M}$ -dependent reaction occurring when pNBTEA transfers from its initial binding site to the second site in the transmembrane domain. The reason this reaction would not be diffusion-limited is that the bulky *p*-nitrobenzyl moiety would have to be accommodated in the space between the transmembrane helices. The possibility that an enzyme conformational change could move bound pNBTEA in the electric field cannot be ruled out; however, that movement would have to dissipate the same fraction of the membrane electric field as extracellular K⁺ binding. This possibility also seems to be unlikely. Thus, a scenario to explain $V_{\rm M}$ -dependent inhibition by pNBTEA is that it moves to a K^+ coordination site in the enzyme's transmembrane domain from its initial peripheral binding site. The effect of the membrane electric field is then to bias the binding site toward the transmembrane helices, deeper into a binding pocket in the enzyme.

The second question is whether *p*NBTEA inhibits the Na⁺,K⁺-ATPase with high enough affinity that these compounds warrant further investigation as possible enzyme blockers. Amine-containing compounds were first shown to inhibit the Na⁺,K⁺-ATPase in a manner that is competitive with extracellular K^+ in the 1960s (Sachs and Conrad, 1968). In that article and subsequent reports (Kropp and Sachs, 1977; Forbush, 1988), amine concentrations were generally in the millimolar range, much too high to consider for pharmacological applications. Even BTEA, the first of the $V_{\rm M}$ dependent inhibitors to be reported, inhibited Na⁺,K⁺-pump current (at 0 mV) by 50% at a concentration of 4 mM (Peluffo et al., 2004). Therefore, we synthesized pNBTEA to determine whether an amine-containing compound could inhibit the Na⁺,K⁺-ATPase at lower concentrations, and, in our initial report (Peluffo et al., 2009), its $V_{\rm M}$ -dependent inhibi-

tion was studied at a concentration of 100 μ M. We did not, however, investigate the apparent binding affinity for pNBTEA. To determine that value, we have examined the concentration and voltage dependence of charge movements that, as shown previously (Peluffo et al., 2004, 2009), represent the binding steps for BTEA and *p*NBTEA. In our experiments, the Na⁺, K⁺-ATPase is trapped in phosphorylated E_2 states (Peluffo and Berlin, 1997). Therefore, charge movements represent net redistribution of enzyme conformations between two steady-state conditions and thereby provide an approximation of equilibrium pNBTEA binding. Thus, steady-state distribution of charge (q_{ON}) was used to estimate the apparent affinity of pNBTEA binding as 7 μ M. In fact, even the Scheme A model, which fit the data with greater error, also predicted that binding occurred with similar affinity (8 μ M). Thus, the prediction of high-affinity binding seems to be independent of the model used.

A final question is, could a $V_{\rm M}$ -dependent inhibitor of the Na⁺,K⁺-ATPase be a beneficial pharmacologic agent? To date, $V_{\rm M}$ -dependent Na⁺, K⁺-ATPase inhibitors contain ammonium moieties, as in *p*NBTEA, and thus all are likely to inhibit more strongly at negative membrane potentials. With these compounds, highly polarized tissues such as healthy cardiac ventricular muscle would be preferentially inhibited compared with more depolarized tissue, such as ischemic heart muscle whose membrane potential is reported to as much as 35 mV less negative than surrounding well perfused muscle (Wit and Janse, 1993). In fact, myocardial ischemia is a frequent complication in heart failure according to the Digitalis Investigation Group (1997), the largest clinical study of digoxin therapy for treatment of congestive heart failure, with 65% of patients having a history of myocardial infarction and 27% having on-going angina. This same study documented the finding that, given digoxin, patients with ischemic heart disease showed worse outcomes (higher rate of hospitalization and mortality) than patients with nonischemic heart failure. Likewise, digoxin was found to be an independent risk factor for excess mortality in patients surviving myocardial infarction (Leor et al., 1995). These clinical data suggest that myocardial ischemia increases the risk of digoxin-induced toxicity (i.e., arrhythmogenesis).

The reason for digoxin's excess morbidity and mortality with ischemic heart disease may well reflect the propensity for ischemic heart tissue to develop cardiac glycoside-induced arrhythmias compared with normal tissue (Lynch et al., 1986; Mazur and Anderson, 1998). Thus, one approach to minimizing arrhythmogenesis with ischemic tissue is to use a $V_{\rm M}$ -dependent Na⁺,K⁺-ATPase inhibitor that preferentially inhibits highly polarized (i.e., well perfused) heart muscle while being relatively less effective in depolarized, ischemic cardiac tissue. A $V_{\rm M}$ -dependent inhibitor with properties similar to those of *p*NBTEA will have such a preference to inhibit Na⁺,K⁺-ATPase in highly polarized cells.

Conceptually, it should also be possible to develop a Na⁺,K⁺-ATPase inhibitor that has the opposite $V_{\rm M}$ dependence, inhibiting depolarized tissues preferentially over highly polarized tissue. Such an inhibitor might be useful for a glycoside developed as a chemotherapeutic agent that would spare muscle and nerve tissue from unwanted drug actions. Whether clinically useful $V_{\rm M}$ -dependent Na⁺,K⁺-ATPase inhibitors can be developed remains to be deter-

mined; however, the present results suggest that the development of such agents should be feasible.

Acknowledgments

We thank Renee Green for technical assistance and Brenda Montalvo-Ortiz and Dr. Sanjay Malhotra for synthesizing pNBTEA.

Authorship Contributions

Participated in research design: Berlin and Peluffo.

Conducted experiments: Berlin and Peluffo.

Contributed new reagents or analytic tools: Berlin.

Performed data analysis: Berlin and Peluffo.

Wrote or contributed to the writing of the manuscript: Berlin and Peluffo.

References

- Akera T and Brody TM (1977) The role of Na⁺,K⁺-ATPase in the inotropic action of digitalis. *Pharmacol Rev* **29:**187–220.
- Blanco-Arias P, Einholm AP, Mamsa H, Concheiro C, Gutiérrez-de-Terán H, Romero J, Toustrup-Jensen MS, Carracedo A, Jen JC, Vilsen B, et al. (2009) A C-terminal mutation of ATP1A3 underscores the crucial role of sodium affinity in the pathophysiology of rapid-onset dystonia-parkinsonism. *Hum Mol Genet* 18:2370–2377.
- Burnham KP and Anderson DR (2002) Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach, 2nd ed, Springer-Verlag, New York.
- De Fusco M, Marconi R, Silvestri L, Átorino L, Rampoldi L, Morgante L, Ballabio A, Aridon P, and Casari G (2003) Haploinsufficiency of ATP1A2 encoding the Na⁺/K⁺ pump α 2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 33:192–196.
- Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med **336:**525–533.
- Eisner DA, Lederer WJ, and Vaughan-Jones RD (1984) The quantitative relationship between twitch tension and intracellular sodium activity in sheep cardiac Purkinje fibres. J Physiol **355**:251–266.
- Forbush B 3rd (1987) Rapid release of ⁴²K and ⁸⁶Rb from an occluded state of the Na,K-pump in the presence of ATP or ADP. J Biol Chem **262**:11104-11115.
- Forbush B 3rd (1988) The interaction of amines with the occluded state of the Na,K-pump. J Biol Chem 263:7979-7988.
- Gadsby DC, Rakowski RF, and De Weer P (1993) Extracellular access to the Na,K pump: pathway similar to ion channel. *Science* **260**:100–103.
- Gheorghiade M, van Veldhuisen DJ, and Colucci WS (2006) Contemporary use of digoxin in the management of cardiovascular disorders. *Circulation* **113**:2556–2564. Glynn IM (1964) The action of cardiac glycosides on ion movements. *Pharmacol Rev*
- **16:**381-407. Glynn IM (1985) The Na⁺,K⁺-transporting adenosine triphosphatase, in *The En*-
- zymes of Biological Membranes (Martonosi AN ed) vol 3, pp 35–114, Plenum Press, New York.
- Glynn IM, Howland JL, and Richards DE (1985) Evidence for the ordered release of rubidium ions occluded within the Na,K-ATPase of mammalian kidney. J Physiol 368:453-469.
- Gobbini M and Cerri A (2005) Digitalis-like compounds: the discovery of the Oaminoalkyloxime group as a very powerful substitute for the unsaturated gammabutyrolactone moiety. *Curr Med Chem* 12:2343–2355.
- González-Lebrero RM, Kaufman SB, Montes MR, Nørby JG, Garrahan PJ, and Rossi RC (2002) The occlusion of Rb⁺ in the Na⁺/K⁺-ATPase. I. The identity of occluded states formed by the physiological or the direct routes: occlusion/deocclusion kinetics through the direct route. *J Biol Chem* **277**:5910–5921.
- Güntert TW and Linde HHA (1981) Chemistry and structure-activity relationships of cardioactive steroids, in *Cardiac Glycosides* (Greeff K ed) pp 13–24, Springer Verlag, Berlin.
- Haas M, Askari A, and Xie Z (2000) Involvement of Src and epidermal growth factor receptor in the signal-transducing function of Na⁺/K⁺-ATPase. J Biol Chem 275: 27832–27837.
- Hilgemann DW (1994) Channel-like function of the Na,K pump probed at microsecond resolution in giant membrane patches. *Science* 263:1429–1432.
- Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of

Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.

- Ishizuka N, Fielding AJ, and Berlin JR (1996) Na pump current can be separated into ouabain-sensitive and -insensitive components in single rat ventricular myocytes. Jpn J Physiol 46:215-223.
- Kropp DL and Sachs JR (1977) Kinetics of the inhibition of the Na-K pump by tetrapropylammonium chloride. J Physiol 264:471–487.
- Larre I, Lazaro A, Contreras RG, Balda MS, Matter K, Flores-Maldonado C, Ponce A, Flores-Benitez D, Rincon-Heredia R, Padilla-Benavides T, et al. (2010) Ouabain modulates epithelial cell tight junction. Proc Natl Acad Sci USA 107:11387–11392.
- Leor J, Goldbourt U, Behar S, Boyko V, Reicher-Reiss H, Kaplinsky E, and Rabinowitz B (1995) Digoxin and mortality in survivors of acute myocardial infarction: observations in patients at low and intermediate risk. The SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. Cardiovasc Drugs Ther 9:609-617.
- Lingrel JB (2010) The physiological significance of the cardiotonic steroid/ouabainbinding site of the Na,K-ATPase. Annu Rev Physiol 72:395-412.
- Lynch JJ, Montgomery DG, and Lucchesi BR (1986) Facilitation of lethal ventricular arrhythmias by therapeutic digoxin in conscious post infarction dogs. Am Heart J 111:883–890.
- Mazur A and Anderson ME (1998) Digoxin and cardiac arrhythmias: an update. Card Electrophysiol Rev 2:222-224.
- Montes MR, González-Lebrero RM, Garrahan PJ, and Rossi RC (2004) Quantitative analysis of the interaction between the fluorescent probe eosin and the Na⁺/K⁺-ATPase studied through Rb⁺ occlusion. *Biochemistry* **43**:2062–2069.
- Newman RA, Yang P, Pawlus AD, and Block KI (2008) Cardiac glycosides as novel cancer therapeutic agents. *Mol Interv* 8:36–49.
- Ogawa H, Shinoda T, Cornelius F, and Toyoshima C (2009) Crystal structure of the sodium-potassium pump (Na⁺,K⁺-ATPase) with bound potassium and ouabain. *Proc Natl Acad Sci USA* **106**:13742–13747.
- Peluffo RD (2004) Effect of ADP on Na⁺-Na⁺ exchange reaction kinetics of Na⁺-Na⁺-ATPase. Biophys J 87:883-898.
- Peluffo RD and Berlin JR (1997) Electrogenic K⁺ transport by the Na⁺-K⁺ pump in rat cardiac ventricular myocytes. J Physiol **501**:33–40.
- Peluffo RD, González-Lebrero RM, Kaufman SB, Kortagere S, Orban B, Rossi RC, and Berlin JR (2009) Quaternary benzyltriethylammonium ion binding to the Na,K-ATPase: a tool to investigate extracellular K⁺ binding reactions. *Biochemistry* 48:8105–8119.
- Peluffo RD, Hara Y, and Berlin JR (2004) Quaternary organic amines inhibit Na,K pump current in a voltage-dependent manner: direct evidence of an extracellular access channel in the Na,K-ATPase. J Gen Physiol 123:249-263.
- Ratheal IM, Virgin GK, Yu H, Roux B, Gatto C, and Artigas P (2010) Selectivity of externally facing ion-binding sites in the Na/K pump to alkali metals and organic cations. Proc Natl Acad Sci USA 107:18718-18723.
- Sachs JR and Conrad ME (1968) Effect of tetraethylammonium on the active cation transport system of the red blood cell. Am J Physiol **215:**795–798.
- Tian J, Cai T, Yuan Z, Wang H, Liu L, Haas M, Maksimova E, Huang XY, and Xie ZJ (2006) Binding of Src to Na⁺/K⁺-ATPase forms a functional signaling complex. Mol Biol Cell 17:317–326.
- Tian J, Li X, Liang M, Liu L, Xie JX, Ye Q, Kometiani P, Tillekeratne M, Jin R, and Xie Z (2009) Changes in sodium pump expression dictate the effects of ouabain on cell growth. *J Biol Chem* **284:**14921–14929.
- Tobin T, Akera T, Brody SL, Ku D, and Brody TM (1975) Cassaine: mechanism of inhibition of Na⁺+K⁺ATPase and relationship of this inhibition to cardiotonic actions. *Eur J Pharmacol* **32:**133–145.
- Wit AL and Janse MJ (1993) The Ventricular Arrhythmias of Ischemia and Infarction, Futura Publishing Comp, Mt. Kisco, New York.

Wuddel I and Apell HJ (1995) Electrogenicity of the sodium transport pathway in the Na,K-ATPase probed by charge-pulse experiments. *Biophys J* 69:909-921.

Yamaoka K, Nakagawa T, and Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175.

Yatime L, Laursen M, Morth JP, Esmann M, Nissen P, and Fedosova NU (2011) Structural insights into the high affinity binding of cardiotonic steroids to the Na⁺, K⁺-ATPase. J Struct Biol 174:296–306.

Address correspondence to: Dr. Joshua R. Berlin, Department of Pharmacology and Physiology, UMDNJ-New Jersey Medical School, 185 S. Orange Ave., Newark, NJ 07101-1709 E-mail: berlinjr@umdnj.edu